In defense of pharmacoepidemiology — embracing the yin and yang of drug research

From the New England Journal of Medicine

By Jerry Avorn, MD

SUMMARY: In this NEJM Perspective, Dr. Avorn defends the field of pharmacoepidemiology against critics who argue that observational data are inherently unreliable and that only randomized controlled trials can provide valid evidence about drug effects. Avorn argues for a both/and approach — the yin and yang of drug research — in which RCT and observational methods complement each other, each suited to answering different kinds of questions. He addresses concerns about confounding and bias in pharmacoepidemiological research while arguing that dismissing the field entirely leaves clinicians, patients, and regulators without crucial information about how drugs perform in real-world populations over extended periods. (Note: Full text paywalled; summary based on publicly available title, description, and field context.)

BACKGROUND: Pharmacoepidemiology — the study of drug use and effects in real-world populations using observational data — has been criticized for methodological limitations compared to randomized controlled trials.

KEY FINDINGS: Not fully retrievable from publicly available text; article is paywalled. The piece argues for complementary use of both RCT and observational methods, each suited to different questions about drug safety and effectiveness.

IMPLICATIONS: Dismissing observational pharmacoepidemiology in favor of RCTs alone leaves critical gaps in knowledge about how drugs perform in the real-world populations of patients who actually take them.